Compare Adaptive Biotechnologies Corp (ADPT) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Southern Copper Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.11 (market cap $3.33B), while Southern Copper Corp trades at $166.06 (market cap $141.63B). The key difference: Southern Copper Corp is far larger — about 42.5× Adaptive Biotechnologies Corp's market cap, and Southern Copper Corp pays a 2.36% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SCCO | |
|---|---|---|
Market Cap | $3.33B | $141.63B |
Sector | Health | Basic Materials |
52-Week High | $22.37 | $218.85 |
52-Week Low | $10.24 | $90.54 |
Enterprise Value | $3.19B | $143.68B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Southern Copper (SCCO) trades at $169.75, down 1.31% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 34.13% net income margin and robust earnings beats in recent quarters. Revenue growth accelerated to $13.42B in 2025, and the company maintains a solid cash flow profile with $4.75B from operations. Recent corporate actions include a $1.00 dividend and a minor stock split.
SCCO's outlook is supported by copper demand linked to AI infrastructure, but high valuation ratios (P/E 29.44) and bearish technicals pose risks. Analyst consensus is cautious with a $151.21 price target below the current price. Key risks include commodity price volatility and execution challenges in mining operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
